Pinsent Masons advises Teva on £603 million sale of Actavis’ UK and Ireland generics business

Teva today announced the completion of the sale of the majority of the assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Limited (a subsidiary of Intas Pharmaceuticals Ltd). The sale, first announced in October last year, has completed for an agreed value of £603 million following approval from the European Commission.

Israel-headquartered Teva is a leading global pharmaceutical company and the world’s largest generic medicines producer, whose generic portfolio covers nearly every therapeutic area.

The sale includes a portfolio of generic medicines plus a manufacturing plant in Barnstaple, England. Teva retains a number of Actavis non-overlapping generic products plus certain specialty medicines and OTC (over-the-counter) products, which have been added to Teva’s existing operations.

The Pinsent Masons team was led by corporate partner Andrew Hornigold and life sciences partner, Allistair Booth, supported by a 25-strong team of lawyers.

Commenting on the deal, Andrew Hornigold said: “It’s good to see that this sizeable and very complex deal has received approval from the European Commission as expected. We’re pleased to have worked with longstanding client Teva on such an important deal for the business.”